Omondi, Seline
Kosgei, Jackline
Musula, George
Muchoki, Margaret
Abong’o, Bernard
Agumba, Silas
Ogwang, Caroline
McDermott, Daniel P.
Donnelly, Martin J.
Staedke, Sarah G.
Schultz, Jonathan
Gutman, Julie R.
Gimnig, John E.
Ochomo, Eric
Funding for this research was provided by:
Centers for Disease Control and Prevention
Article History
Received: 6 October 2023
Accepted: 23 November 2023
First Online: 30 November 2023
Declarations
:
: The study was approved by the scientific and ethics review unit (SERU) of the Kenya Medial Research Institute (protocol number KEMRI/SERU/CGHR/123/2776) and by the Institutional Review Board of the US Centers of Disease Control and Prevention (IRB 6728) through a reliance agreement with KEMRI. Written informed consent was obtained from all HLC collectors. The HLC collectors were given doxycycline malaria prophylaxis unless they tested positive for malaria in which case, they were treated with artemisinin-based combination therapy (ACT).
: This study was published with the consent of the KEMRI Director General.
: The authors declare no competing interests.